Real-world Data on the Effectiveness and Safety of Interferon-alpha-2a Intralesional Injection for the Treatment of Focally Recalcitrant Mycosis Fungoides

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2020 Sep 21

PMID 32953720

Authors

Shi-Yu Zhang

Zhao-Rui Liu

Lu Yang

Tao Wang

Jie Liu

Yue-Hua Liu

Kai Fang

Affiliations

Soon will be listed here.

Abstract

Background: Focally recalcitrant mycosis fungoides (MF) is challenging to treat. Despite interferon (IFN)-α intralesional injection having been tested in randomized controlled trials for the treatment of patch or early plaque lesions of MF, no real-world data regarding this therapy for focally recalcitrant MF has been reported. This study aimed to evaluate the effectiveness and safety of IFN-α-2a intralesional injection in focally recalcitrant MF.

Methods: Data on all cases of focally recalcitrant MF treated by IFN-α-2a intralesional injection in Peking Union Medical College Hospital from January 1, 2015 to December 31, 2019 were retrospectively retrieved. Based on clearance of injected lesions and the proportion of adverse events (AEs), the effectiveness and safety of the treatment were analyzed, respectively.

Results: Of the 15 patients included, 10 (66.7%) achieved complete response (CR), and 1 (6.7%) patient had partial response. The overall response rate was 73.3%. The clearance rate of lesions in the sun-exposed areas was significantly higher than that in the non-sun-exposed areas (P<0.01). The CR rate in patients with disease duration of less than 20 years was significantly higher than that in the patients with disease duration of at least 20 years (P<0.05). Four (26.7%) patients had stable disease (SD). The median event-free survival (EFS) was 4.0 months (95% CI, 1.8-6.1 months; range, 1-28+ months). There were no severe acute or chronic side effects.

Conclusions: IFN-α-2a intralesional injection is an effective and safe treatment modality for the treatment of focally recalcitrant MF.

References

Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K . Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014; 32(11):1157-63. DOI: 10.1200/JCO.2013.52.0924. View

Furudate S, Fujimura T, Kakizaki A, Hidaka T, Asano M, Aiba S . Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma. J Dermatol Sci. 2016; 83(3):182-9. DOI: 10.1016/j.jdermsci.2016.05.004. View

McGinnis K, Junkins-Hopkins J, Crawford G, Shapiro M, Rook A, Vittorio C . Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol. 2004; 50(3):375-9. DOI: 10.1016/j.jaad.2003.10.669. View

Jimbow K, Yamana K, Ishida O, Kawamura M, Ito Y, Maeda K . [Evaluation of rIFN-gamma in the treatment of lymphoma and melanoma of the skin by systemic and intralesional administration]. Gan To Kagaku Ryoho. 1987; 14(1):152-8. View

Spaccarelli N, Rook A . The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin. 2015; 33(4):731-45. DOI: 10.1016/j.det.2015.05.008. View

Wolff J, Zitelli J, Rabin B, Smiles K, Abell E . Intralesional interferon in the treatment of early mycosis fungoides. J Am Acad Dermatol. 1985; 13(4):604-12. DOI: 10.1016/s0190-9622(85)70205-8. View

Wagner A, Wada D, Bowen G, Gaffney D . Mycosis fungoides: the addition of concurrent and adjuvant interferon to total skin electron beam therapy. Br J Dermatol. 2013; 169(3):715-8. DOI: 10.1111/bjd.12386. View

Child F, Ortiz-Romero P, Alvarez R, Bagot M, Stadler R, Weichenthal M . Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome. Br J Dermatol. 2016; 175(1):80-8. DOI: 10.1111/bjd.14427. View

Ross C, TINGSGAARD P, Jorgensen H, Vejlsgaard G . Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 1993; 51(2):63-72. DOI: 10.1111/j.1600-0609.1993.tb01595.x. View

10.

Yamamoto T, Sasaki G, Sato T, Katayama I, Nishioka K . Cytokine profile of tumor cells in mycosis fungoides: successful treatment with intra-lesional interferon-gamma combined with chemotherapy. J Dermatol. 1995; 22(9):650-4. DOI: 10.1111/j.1346-8138.1995.tb03892.x. View

11.

Kogure Y, Yoshimi A, Ueda K, Nannya Y, Ichikawa M, Nakamura F . Modified ESHAP regimen for relapsed/refractory T cell lymphoma: a retrospective analysis. Ann Hematol. 2015; 94(6):989-94. DOI: 10.1007/s00277-015-2309-z. View

12.

Wong H . Novel biomarkers, dysregulated epigenetics, and therapy in cutaneous T-cell lymphoma. Discov Med. 2013; 16(87):71-8. View

13.

Dummer R, Eichmuller S, Gellrich S, Assaf C, Dreno B, Schiller M . Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther. 2010; 18(6):1244-7. PMC: 2889748. DOI: 10.1038/mt.2010.52. View

14.

Kim Y, Bagot M, Pinter-Brown L, Rook A, Porcu P, Horwitz S . Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018; 19(9):1192-1204. DOI: 10.1016/S1470-2045(18)30379-6. View

15.

Guenova E, Watanabe R, Teague J, DeSimone J, Jiang Y, Dowlatshahi M . TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013; 19(14):3755-63. PMC: 3715586. DOI: 10.1158/1078-0432.CCR-12-3488. View

16.

Papa G, Tura S, Mandelli F, Vegna M, Defazio D, Mazza P . Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?. Br J Haematol. 1991; 79 Suppl 1:48-51. DOI: 10.1111/j.1365-2141.1991.tb08119.x. View

17.

Herne K, Talpur R, Champlin R, Duvic M . Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sézary syndrome. Blood. 2002; 101(6):2132-6. DOI: 10.1182/blood-2002-07-2247. View

18.

Husken A, Tsianakas A, Hensen P, Nashan D, Loquai C, Beissert S . Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol. 2011; 26(1):71-8. DOI: 10.1111/j.1468-3083.2011.04011.x. View

19.

Yoo E, Cassin M, Lessin S, Rook A . Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol. 2001; 45(2):208-16. DOI: 10.1067/mjd.2001.116345. View

20.

Doerschner M, Pekar-Lukacs A, Messerli-Odermatt O, Dommann-Scherrer C, Rutti M, Muller A . Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement. Br J Dermatol. 2018; 181(6):1296-1302. DOI: 10.1111/bjd.17535. View